前端編輯

管理員身份可於登入後,進行網站的前端管理。

王照元 教授

Jaw-Yuan Wang      

·        連絡電話:07-312-1101 ext. 5105

·        電子信箱: cy614112@ms14.hinet.net; jayuwa@cc.kmu.edu.tw

·        辦公位置:啟川六樓行政室、啟川18ES醫局

專長 

腫瘤外科、消化外科、大腸直腸外科、分子生物學、營養學

研究領域

腫瘤分子生物學、癌症分子標記

學歷

高雄醫學大學博士1999-2003

高雄醫學大學碩士1993-1996

高雄醫學院學士1982-1989

工作經歷

高雄醫學大學附設中和紀念醫院副院長

高雄醫學大學附設中和紀念醫院大腸直腸外科主任

高雄醫學大學附設中和紀念醫院人體生物資料庫主任

高雄醫學大學醫學院臨床醫學研究所教授

高雄醫學大學醫學院外科學教授

教授課程

外科學科

 

歷年在校行政服務

高雄醫學大學醫學研究所碩士班主任2009/08~2012/07

高雄醫學大學醫學系實驗外科學主任2009/08~2012/07

高雄醫學大學醫學院研發組組長2006/08~2009/07

高雄醫學大學基因體醫學研究中心學術推動組組長2002/02~2006/07

高雄醫學大學臨床醫學研究所所長2012/08~2014/07

歷年獲得研究計畫經費補助(近五年)

序號

計畫名稱及編號

補助單位

執行期限

計劃內
擔任之工作

 1

Development of the MMP-2-activated pro-aEGFR/HER2 Ab for selective tumor therapy and reducing side-effects

Ministry of Science and Technology. ROC

2014/05

-present

PI

 2

Biomarkers for the early diagnosis, prediction, prognosis for colorectal cancers

Academia Sinica

2013/01

PI

 3

The prevention early detection/diagnosis, and personalized Therapy of colorectal cancer

Ministry of Health and welfare

2014/01

-present

PI

 4

Integration of tailored therapy and mini-invasive surgery for colorectal cancer

Kaohsiung Medical University Hospital

2014/11

-2015/7

PI

 5

Da Vinci Minimally invasive surgery

Kaohsiung Medical University Hospital

2014/10

-2015/07

PI

 6

Integration of tailored therapy and mini-invasive surgery for colorectal cancer

Kaohsiung Medical University Hospital

2015/8

-2016/7

PI

 7

Prospective analysis of UGT1A promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI as the first-line setting

Kaohsiung Medical University Hospital

2015/08

2016/07

PI

 8

To develop the protease specific (perforin-Grazyme) for targeting colon cancer therapy

Kaohsiung Medical University

2015/09

2016/07

PI

 9

Da Vinci Minimally invasive surgery

Kaohsiung Medical University Hospital

2015/08

-2016/07

PI

 10

Integration of tailored therapy and mini-invasive surgery for colorectal cancer

Kaohsiung Medical University Hospital

2016/8

-present

PI

 11

Prospective analysis of UGT1A promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI as the first-line setting

Kaohsiung Medical University Hospital

2016/08

-present

PI

 12

Da Vinci Minimally invasive surgery

Kaohsiung Medical University Hospital

2016/08

-present

PI

 產學合作計畫

序號

計劃名稱

委託機構

執行期限

計劃內
擔任之工作

Hi-Q 小分子褐藻醣膠於大腸直腸癌上的輔助使用

Hi-Q Marine Biotech International Ltd    

中華海洋生技股份有限公司

103/07/01-105/06/30

分項計畫主持人

Hi-Q Fucoidam Erbitux於大腸直腸癌治療的協同效果

中華海洋生技股份有限公司

105/10/1-107/9/30

分項計畫主持人

專利

年度

國別

專利/技轉名稱

成果產出歸屬計畫

(專屬或非專屬授權)

專利證

書號碼

發明人

專利期限

96

中華

民國

用於診斷大腸直腸癌之組合物

90-2317-B-037-075

發明第I278519

林綉茹

王照元

2007/04/00 ~

2023/12/00

97

美國

用於診斷大腸直腸癌之組合物

90-2317-B-037-075

7575928

林綉茹

王照元

2009/08/00~

2028/08/00

100

歐盟

用於診斷人類大腸直腸癌的基因群

90-2317-B-037-075

 EP1564302

林綉茹

王照元

2011/10/00~

2030/09/

100

日本

用於診斷人類大腸直腸癌的基因群

90-2317-B-037-075

2004-044186

林綉茹

王照元

2011/10/00~

2030/09/00

104

中華

民國

用於抑制結腸直腸癌及子宮上皮癌生長轉移之醫藥組合物

100-2320-B-037-002

發明第I504404

張偉嶠

王照元

王堉璿

卓夙航

2015/10/21

~

2030/07/21

102

美國

以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直

99-2320-B-037-014-MY3

US8,420,618

卓夙航

王照元

楊以屏

蔡祥麟

2013/04/16

~

2020/10/16

104

美國

以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直

99-2320-B-037-014-MY3

US8,940,480

卓夙航

王照元

楊以屏

蔡祥麟

2015/01/27

~

2022/10/16

105

中華

民國

以微小去氧核醣核酸為基礎用於抗大腸直腸癌及大腸直

99-2320-B-037-014-MY3

發明第I546075

卓夙航

王照元

楊以屏

蔡祥麟

2016/08/21

~

2031/06/22

105

中華

民國

大腸癌的檢測方法及其應用

102-2628-B-037-002-MY3

發明第I521207

王照元

郭柏麟

甘蓉瑜

2016/2/11

~

2034/12/30

105

中華

民國

衛教輔助裝置

發明第M523462

王照元

孫麗珠

石英鈴

2016/6/11

~

2026/1/11

104

中華

民國

非類固醇消炎止痛藥物之用途

申請中

張偉嶠

王照元

黃旼儀

王堉璿

 

 

期刊論文發表(近五年)

1.         Chuang YP, Wang JY, Jao SW, Wu CC, Chen JH, Hsiao KH, Lin CY, Chen SH, Su SY, Chen YJ, Chen YT, Wu DC, Li LH. Over-expression of AURKA, SKA3 and DSN1 contributes to colorectal adenoma to carcinoma progression. Oncotarget. 2016. MOST104-2325-B-037-001, MOHW105- TDU-B-212-134007, Health and welfare surcharge of tobacco products, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

2.         Yang IP, Tsai HL, Huang CW, Lu CY, Miao ZF, Chang SF, Juo SH, Wang JY*. High Blood Sugar Levels Significantly Impact the Prognosis of Colorectal Cancer Patients through Down-regulation of MicroRNA-16 by Targeting Myb and VEGFR2. Oncotarget. 2016 Feb 25. MOST103-2314-B-037-010-MY3, MOHW105-TDU-B-212-134005, Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR).

3.         Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY*. Development of a Deregulating microRNA Panel for the Detection of Early Relapse in Postoperative Colorectal Cancer Patients. J Transl Med 2016 Apr 29;14(1):108. (MOHW105-TDU-B-212-134007), (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001); (MOST104-2325-B-037-001); (KMUH103-3M39; KMUH103-3M58; KMUH104-4M51); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Medicine, Research & Experimental, IF: 3.930, Ranking: 26/123, 2014 JCR).

4.         Kan JY, Yen MC, Wang JY, Wu DC, Chiu YJ, Ho YW, Kuo PL. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget. 2016 May 2.

5.         Su WC, Tsai HL, Yeh YS, Huang CW, Chen FM, Wang JY*. Successful Management of Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Three Case Reports and Literature Review. J Soc Colon Rectal Surgeon (Taiwan) 2016;27:83-89.

6.         Chen YT, Tsao SC, Tsai HP, Wang JY, Chai CY. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. J Clin Pathol. 2016 Apr 22.

7.         Huang CW, Yeh YS, Ma CJ, Tsai HL, Chen CW, Huang MY, Lu CY, Wu JY, Wang JY*. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as a First-Line Treatment. Chemotherapy (Accepted in 2016). MOST104-2325-B-037-001); (MOHW 105-TDU-B-212-134007), (KMUH104-4M29, KMUH104-4R19, KMUH-S10415, KMUH-S10418,); (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP103H10, KMU-TP103H11, KMU-PT104002, KMU-DK105001, D08-00005-10401); (KMU-TP104A11), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

8.         Huang CW, Yeh YS, Su WC, Tsai HL, Choy TK, Huang MY, Huang CM, Wu IC, Hu HM, Hsu WH, Su YC, Wang JY*. Robotic Surgery with High Dissection and Low Ligation Technique for Consecutive Patients with Rectal Cancer Following Preoperative Concurrent Chemoradiotherapy.  Int J Colorectal Dis 2016 Jun;31(6):1169-77. MOHW105-TDU-B-212-134007, KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001; MOST104-2325-B-037-001; KMUH103-3M39; KMUH103-3M58; KMUH104-4M51; and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Surgery, IF: 2.449, Ranking: 55/198, 2014 JCR).

9.         Tsai HL, Huang CW, Chen CW, Yeh YS, Ma CJ, Wang JY*. Survival in Resected Stage II Colorectal Cancer Is Dependent on Tumor Depth, Vascular Invasion, Postoperative CEA Level, and The Number of Examined Lymph Nodes. World J Surg 2016 Apr;40(4):1002-9. (Category: Surgery, IF: 2.642, Ranking: 47/198, 2014 JCR). MOST104-2325-B-037-001; MOHW 104-TDU-B-212-124-003, KMUH100-OM16, KMUH103-3R16, KMUHS10304,KMUHS10305; KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, KMU-TP104A11); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

10.     Chen YT, Tsao SC, Tsai HP, Wang JY, Chai CY. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy. Virchows Arch 2016 Feb 25. (Category: Pathology, IF: 2.651, Ranking: 23/76, 2014 JCR).

11.     Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, Wang JY*. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016 Jan 25;17(1):46. MOST103-2314-B-037-010-MY3, MOHW105-TDU-B-212-134005, Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. (Category: Medicine, Research & Experimental, IF: 1.731, Ranking: 81/123, 2014 JCR).

12.     Huang MY, Huang CM, Tsai HL, Huang CW, Hsieh HM, Yeh YS, Wu JY, Wang WM, Wang JY*. Comparison of adjuvant FOLFOX4 chemotherapy versus oral UFT/LV following adjuvant FOLFOX4 chemotherapy in stage III colon cancer patients after radical resection. Oncology Letters 2015 (Accepted), MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003, KMUH103-3M03, KMUHS10418, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11. (Category: Oncology, IF: 1.554, Ranking: 173/211, 2014 JCR).

13.     Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ, Yeh YS, Chang SF, Huang ML, Wang JY*. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting. Transl Oncol 2015 Dec;8(6):474-9. MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003, KMUH102-2M46, KMUH103-3M39, KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. (Category: Oncology, IF: 2.884, Ranking: 105/211, 2014 JCR).

14.     Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S, Chang WC*. STIM1 Overexpression Promotes Colorectal Cancer Progression, Cell Motility and COX-2 Expression. Oncogene 2015 Aug 13;34(33):4358-67. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C03. SCI. (Category: Oncology, IF: 8.459, Ranking: 13/211, 2014 JCR).

15.     Chen KC, Liao YC, Wang JY, Lin YC, Chen CH, Juo SH. Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. Oncotarget 2015 Sep 15;6(27):24105-18. SCI. (Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR).

16.     Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, Wang JY, Cheng CM, Chen CS, Cheng TL. Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. PLoS One. 2015 Jul 17;10(7):e0133470. SCI. (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).

17.     Huang CW, Tsai HL, Huang MY, Huang CM, Yeh YS, Ma CJ, Wang JY*. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World J Surg Oncol. 2015 Aug 28;13:257. SCI. (Category: Surgery, IF=1.408; Ranking: 107/198, 2014 JCR).

18.     Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, Wang JY*. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. PLoS One. 2015 Apr 28;10(4):e0123973. SCI. (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).

19.     Yeh YS, Huang YH, Lin HC, Shih YL, Lu CY, Wang JY*. J Gastrointest Dig Syst S Long-Term Recurrent Liposarcoma of the Mediastinum with Gastric Metastasis: A Case Report. 2015;S13:1.

20.     Huang CW, Yeh YS, Ma CJ, Choy TK, Huang CM, Hsu WH, Wang JY*. Robotic colorectal surgery for laparoscopic surgeons with limited experience:  Preliminary experiences for 40 consecutive cases at a single medical center. BMC Surg 2015 Jun 18;15:73. MOST103-2325-B-037-005, MOHW103-TD-B-111-05, KMUH103-3R16, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Surgery, IF=1.397; Ranking: 108/198, 2014 JCR).

21.     Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ, Jian SF, Hung JY, Wang JY*, Kuo PL*. Chemokine (C-C motif) ligand 5 is involved in tumor-associated dendritic cell-mediated colon cancer progression through noncoding RNA MALAT-1. J Cell Physiology 2015 Aug;230:1883-94. SCI. (Category: Physiology, IF=3.839; Ranking: 15/83, 2014 JCR). (Equally contributed corresponding author).

22.     Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY*. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol 2015 Feb 1;8(2):1900-10. SCI. (Category: Pathology, IF=1.895; Ranking: 40/75, 2014 JCR).

23.     Lee YC, Yin TC, Chen YT, Chai CY, Wang JY, Liu MC, Lin YC, Kan JY. High Expression of Phospho-H2AX Predicts a Poor Prognosis in Colorectal Cancer. Anticancer Res 2015 Apr;35:2447-53. SCI. (Category: Oncology, IF: 1.826, Ranking: 162/211, 2014 JCR).

24.     Huang MY, Lin CH, Huang CM, Tsai HL, Huang CW, Yeh YS, Chai CY, Wang JY*. Relationships between SMAD3 Expression and Preoperative Fluoropyrimidine-Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients. World J Surg 2015 May;39(5):1257-67. MOST103-2325-B-037-005 and MOHW 104-TDU-B-212-124-003, KMUH103-3R16, KMUHS10304, KMUHS10305, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Surgery, IF=2.642; Ranking: 47/198, 2014 JCR).

25.     Ma CJ, Wu JM, Tsai HL, Huang CW, Lu CY, Sun LC, Shih YL, Chen CW, Chuang JF, Wu MH, Wang MY, Lin MS, Wang JY*. Prospective Double-Blind Randomized Study on the Efficacy and Safety of an n-3 Fatty Acid enriched intravenous fat emulsion in Postsurgical Gastric and Colorectal Cancer Patients. Nutr J 2015 Jan 21;14:9. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C00. SCI. (Category: Nutrition & Dietetics, IF=2.597; Ranking: 36/77, 2014 JCR).

26.     Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL*. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 2014 Dec;35(37):9930-40 SCI. (Category: Materials Science, Biomaterials, IF: 8.312, Ranking: 1/32, 2013 JCR). (Equally contributed first author). MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

27.     Chuang KH, Kao CH, Roffler SR, Lu SJ, Cheng TC, Wang YM, Chuang CH, Hsieh YC, Wang YT, Wang JY, Weng KY, Cheng TL*. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 2014. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: in Polymer Science, IF=5.927, Ranking: 3/82, 2013 JCR).

28.     Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy. Mol Cancer Ther 2014 Dec;13(12):2852-63. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI (Category: Oncology, IF: 6.107, Ranking: 23/202, 2013 JCR).

29.     Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, Lee SW, Lee HH, Fang JL, Huang WT, Chen SH. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec;67(12):1056-61. MOHW103-TD-B-111-05. SCI.

30.     Tsai PC, Huang SW, Tsai HL, Ma CJ, Hou MF, Wang YS, Juo SH, Wang JY*. The association between DNA copy number aberrations at chromosome 5q22 and gastric cancer. PLoS One 2014 Sep 11;9(9):e106624. KMUH98-8I04, KMUH98-8G05, KMUH99-9R03, MOHW103-TD-B-111-05, NSC 99-2320-B-037-014-MY3, NSC 94-2314B037-104. SCI. (Category: Multidisciplinary Sciences, IF: 3.534, Ranking: 8/55, 2013 JCR).

31.     Cheng DE, Tsai YM, Hsu YL, Hou MF, Tsai EM, Wang JY, Kan JY, Kuo PL. Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation. Oncol Lett 2014 Aug;8(2):620-626. SCI.

32.     Cheng AL, Li J, Vaid AK, Ma B, Teh CS, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes Jr. G, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus. Clinical Colorectal Cancer 2014 Sep;13(3):145-55. SCI

33.     Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY*. FOLFIRI and Regorafenib Combination Therapy with Dose Escalation of Irinotecan as Fourth-Line Treatment for Metastatic Colon Cancer Patients According to Uridine Diphosphate-Glucuronosyltransferase 1A1 Genotyping. OncoTargets_and_Therapy 2014 Nov 21;7:2143-2146. MOHW103-TD-B-111-05; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan; NSC 99-2320-B-037-014-MY3; KMUH98-8G64, KMUH102-2R18. SCI

34.     Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Lin SR. Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip. Tumour Biol. 2014 Oct;35(10):9639-47. (MOHW103-TD-B-111-05), the Kaohsiung Medical University Hospital (KMUH101-1M66, KMUH102-2M46), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

35.     He HL, Lee YE, Shiue YL, Lee SW, Lin LC, Chen TJ, Wu TF, Hsing CH, Huang HY, Wang JY, Li CF. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. J Surg Oncol 2014 Aug 22. 110(8):1002-10. SCI.

36.     Huang CM, Huang CW, Huang MY, Lin CH, Chen CF, Yeh YS, Ma CJ, Huang CJ, Wang JY*. Co-existence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapy. Med Princ Pract 2014;23(5):465-70. MOHW103-TD-B-111-05, KMUH100-0M49, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

37.     Lu CY, Huang CW, Hu HM, Tsai HL, Huang CM, Yu FJ, Huang MY, Chang SF, Huang ML*, Wang JY*. The Prognostic Advantage of Irinotecan Dose Escalation According to UGT1A1 Genotyping in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in a First-line Setting. Transl Res 2014 Aug;164(2):169-76. MOHW103-TD-B-111-05, KMUH96-6G03 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medical Laboratory Technology, IF: 5.030, Ranking: 2/30, 2014 JCR).

38.     Huang MY, Chen CF, Huang CM, Tsai HL, Yeh YS, Ma CJ, Wu CH, Lu CY, Chai CY, Huang CJ, Wang JY*. Helical Tomotherapy Combined with Capecitabine in The Preoperative Treatment of Locally Advanced Rectal Cancer. Biomed Res Int 2014;2014:352083. MOHW103-TD-B-111-05, KMUH99-9M07, KMUH101-1M66, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

39.     Huang MY, Liu HC, Yen LC, Chang JY, Huang JJ, Wang JY, Hsiao CP, Lin SR. Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. J Transl Med 2014, 12:147. NSC 99-2320-B-242-002-MY3, MOHW103-TD-B-111-5), KMUH101-1 M66, KMUH102-2 M46, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medicine, Research & Experimental, IF: 3.991, Ranking: 24/122, 2013 JCR).

40.     Sun LC, Tai YY, Liao SM, Lin TY, Shih YL, Chang SF, Huang CW, Chan HM, Huang CJ, Wang JY*. Clinical Characteristics of Second Primary Cancer in Colorectal Cancer Patients: the impact of colorectal cancer or other second cancer occurring first. World J Surg Oncol 2014;Mar 28;12(1):73. MOHW103-TD-B-111-05, KMUH100-OR16 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

41.     Tsai YT, Chang CM, Wang JY, Hou MF, Wang JM, Shiurba R, Chang WC, Chang WC*. Function of DNA methyltransferase 3a in lead (Pb2+ )-Induced Cyclooxygenase-2 gene. Environ Toxicol. 2014 Mar 17. SCI.

42.     Tsai HL, Lin CH, Cheng YL, Huang CW, Wang JY*. Rectal Carcinoma in a Young Female Patient with Peutz-Jeghers Syndrome: A Case Report. Med Princ Pract. 2014;23(1):89-91. SCI.

43.     Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. SCI.

44.     Su CH, Yu FJ, Tsai HL, Wang JY*. Endoscopic Closure of Colonic Fistulas in Colon Cancer Patients Using a Combination of Hemoclips and Endoloops: Two Case Reports. Techniques in Coloproctology. 2014 Feb;18(2):205-8. DOH101-TD-C-111-002. SCI.

45.     Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS, Lee SC, Wang WM. Discovery of tumor markers for gastric cancer by proteomics. PLoS One. 2014 Jan 3;9(1):e84158. SCI.

46.     Ma YS, Yang IP, Tsai HL, Huang CW, Juo SH, Wang JY*. High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells. DNA Cell Biol 2014 Feb;33(2):64-72. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

47.     Yeh YS, Huang ML, Chang SF, Chen CF, Hu HM, Wang JY*. FOLFIRI Combined with Bevacizumab as the First-line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping. Med Princ Pract 2014;23(5):478-81. DOH102-TD-C-111-002, KMUH96-6G03 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

48.     Huang MY, Wu CH, Chung FY, Huang CM, Huang CW, Tsai HL, Chen CF, Lin SR*, Wang JY*. DPYD, TYMS, TYMP, TK1, and TK2 Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy. Biomed Res Int 2013;2013:931028. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

49.     Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY*. The Prognostic Values of EGFR Expression and KRAS Mutation in Patients with Synchronous/Metachronous Metastatic Colorectal Cancer. BMC Cancer. 2013 Dec 13;13(1):599. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

50.     Kan JY, Hsu YL, Chen YH, Chen TC, Wang JY*, Kuo PL*. Gemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cells. Biomed Res Int 2013 Dec 13;13:599. doi: 10.1155/2013/159786. Epub 2013 Dec 10. DOH102-TD-C-111-002. SCI.

51.     Huang MY, Tsai HL, Lin CH, Huang CW, Ma CJ, Huang CM, Lin IL, Lu CY, Chai CY, Wang JY*. Predictive Value of ERCC1, ERCC2, and XRCC1 Overexpression for Stage III Colorectal Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. J Surg Oncol 2013 Dec;108(7):457-64. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

52.     Tsai HL, Yang IP, Huang CW, Ma CJ, Kuo CH, Lu CY, Juo SH, Wang JY*. Clinical significance of miRNA-148a for early relapse of stage II and III colorectal cancer patients following curative resection. Translation Research 2013 Oct;162(4):258-68. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Category: Medical Laboratory Technology, IF: 5.030, Ranking: 2/30, 2014 JCR).

53.     Huang MY, Yen LC, Liu HC, Liu PP, Chung FY, Wang JY*, Lin SR*. Significant Overexpression of DVL1 in Taiwanese Colorectal Cancer Patients with Liver Metastasis. Int J Mol Sci 2013 Oct 14;14(10):20492-507. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI..

54.     Yang IP, Tsai HL, Juo SH, Huang MY, Hou MF, Wang JY*. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One. 2013 Jun 28;8(6):e66842. NSC99-2320-B-037-014-MY3, KMUH98-8I04, KMUH100-OR16, DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

55.     Chan CP, Tsai YT, Chen YL, Hsu YW, Tseng JT, Chuang HY, Shiurba R, Lee MH, Wang JY*, Chang WC*. Pb2+ induces gastrin gene expression by extracellular signal-regulated kinases 1/2 and transcription factor activator protein 1 in human gastric carcinoma cells. Environ Toxicol. 2013 Jun 14. doi: 10.1002/tox.21878. [Epub ahead of print]. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

56.     Kao LC, Yang PF, Ma CJ, Huang CW, Chen FM, Chan HM, Huang CJ, Hsieh JS, Wang JY*. The Impact of Metastatic Ratio to Harvested Regional Lymph Nodes on Overall Survival in Patients with Stage III Colorectal Cancer: Focus on Numbers of Lymph Node Harvest Less Than 12. J Soc Colon Rectal Surgeon 2013;24(2):37-42.

57.     Wu CH, Chung FY, Chang JY, Wang JY*. Rapid detection of gene expression by a colorectal cancer enzymatic gene chip detection kit. Biomark Genomic Med 2013;5(3):87-91.

58.     Huang MY, Chen HC, Yang IP, Tsai HL, Juo SH, Wang JY*. Analysis of gene expression profiles in tumorigenesis/progression of colorectal cancers using GeXP multiplex assay. Cancer Biomark 2013 April;13(4):269-79. DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. NSC99-2320-B-037-014-MY3, 100-CCH-KMU-002. SCI.

59.     Chen CW, Ma CJ, Shan YS, Yeh YS, Wang JY*. Prospective, Randomized, Controlled Study of Ampicillin/Sulbactam versus Moxifloxacin Monotherapy for the Treatment of Community-Acquired Complicated Intra-Abdominal Infections" in its current form for publication in Surgical Infections. Surg Inf 2013 Aug;14(4):389-96. SCI.

60.     Tsai HL, Wang JY*. Predictors of response in locally advanced rectal cancer following concurrent chemoradiotherapy. Biomark Genomic Med 2013;5:8-12. DOH102-TD-C-111-002, Biosignature in Colorectal Cancers, Academia Sinica. Review article.

61.     Huang MY, Wang JY*, Lin SR*. CA9 and CHRNB1 were correlated with perineural invasion in Taiwanese colorectal cancer patients. Biomark Genomic Med 2013;5:84-86.

62.     Chen CF, Chuang CH Hu C, Wang JY*. Ileus secondary to a retroperitoneal malignant melanoma. Biomark Genomic Med 2013;5(3): 113-6..

63.     Chou WW, Chen KC, Wang YS, Wang JY, Liang CL, Juo SH. The role of SIRT1/AKT/ERK pathway in ultraviolet B induced damage on human retinal pigment epithelial cells. Toxicol In Vitro 2013 May 11;27(6):1728-1736. SCI.

64.     Ou CH, Kuo FC, Hsu WH, Lu CY, Yu FJ, Kuo CH, Wang JY, Wu MT, Shiea J, Wu DC, Hu HM. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. J Dig Dis 2013 Sep;14(9):474-83 . SCI.

65.     Chen CW, Tsai HL, Yeh YS, Lin HL, Huang CW, Chen CF, Chang YT, Lou YT, Wang JY*. Osteoporosis self-assessment tool for Asians as a simple risk index for identifying poor prognosis in women surgically treated for colorectal cancer. J Surg Res 2013 May;181(2):242-9. KMUH98-8I04 and KMUH99-9M03; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

66.     Lin CH, Liu CH, Tsai HL, Wang JY, Tsai HP, Chai CY. Expression of OV-6 in primary colorectal cancer and rectal cancer with preoperative chemoradiotherapy: a clinicopathological study. Histopathology 2013 Apr;62(5):742-51. DOH102-TD-111-002. SCI.

67.     Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY*. Circulating Tumor Cells as a Surrogate Marker for Determining Clinical Outcome to mFOLFOX Chemotherapy in Patients with Stage III Colon Cancer. Br J Cancer 2013 Mar 5;108(4):791-7. NSC99-2320-B-037-014-MY3, KMUH98-8I04, DOH102-TD-C-111-002 & Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, 99CM-KMU-02. SCI.

68.     Tsai HL, Yang IP, Yang IP, Chai CY, Huang YH, Chen CF, Hou MF, Kuo CH, Juo SH, Wang JY*. Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection. Int J Colorectal Dis 2013 Mar;28(3):415-24. KMUH98-8I04; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

69.     Huang MY, Wang JY, Huang ML, Chang HJ, Lin SR. Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. Int J Mol Sci 2013 Feb 19;14(2):4121-34. DOH102-TD-111-002, KMUH100-0M48, ZAFGH 100-05, ZAFGH 101-07, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Equally first author).

70.     Tsai HL, Yeh YS, Chang YT, Yang IP, Lin CH, Kuo CH, Juo SH, Wang JY*. Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 2013 Feb;107(2):148-54. KMUH98-8I04; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI.

71.     Yeh YS, Tsai HL, Ma CJ, Wu DC, Lu CY, Wu IC, Hou MF, Wang JY*. A retrospective study of the safety and efficacy of a first-line treatment with mFOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Chemotherapy 2012;58(5):411-8. SCI. DOH102-TD-C-111-002. SCI.

72.     Yang PF, Chen CY, Kao LC, Ma CJ, Chen FM, Chan HM, Huang CJ, Hsieh JS, Wang JY*. Computed Tomography in the Postoperative Surveillance of Stage III Colorectal Cancers Receiving Adjuvant Chemotherapy. J Soc Colon Rectal Surgeon 2012;23(4):144-50.

73.     Huang ML, Kan JY, Ma CJ, Huang CW, Chen FM, Chuang CH, Chan HM, Huang CJ, Chang SF, Wen YH, Wang JY*. An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer. Genomic Med Bio Mark Health Sci 2012:4;122-127. DOH102-TD-C-111-002, ZAFGH 101-07, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

74.     Yang IP, Tsai HL, Hou MF, Chen KC, Tsai PC, Huang SW, Chou WW, Wang JY*, Suh-Hang Hank Juo*. MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle. Carcinogenesis. 2012 Aug;33(8):1522-30. NSC99-2320-B-037-014-MY3; KMUH98-8I04, KMUH100-OR16; DOH101-TD-C-111-002; Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. SCI. (Equally corresponding authors).

75.     Chen CW, Chen MJ, Yeh YS, Tsai HL, Chang YT, Lu CY, Shih YL, Sun LC, Wang JY*. Intraoperative anastomotic dye test significantly decrease anastomotic leaks in patients with rectal cancers receiving resection. Techniques in Coloproctology. 2013 Oct;17(5):579-83. DOH101-TD-C-111-002. SCI.

76.     Chen YC, Tsai HL, Lin CH, Huang CJ, Wang JY*. Adenosquamous Carcinoma of the Colon: A Case Report. Genomic Med Bio Mark Health Sci 2012;4:103-6.

77.     Chang YT, Lee JY, Chiu CS, Wang JY*. Feasibility of Emergency Laparoscopic Colectomy for Children with Acute Colonic Perforations and Fibropurulent Peritonitis. World J Surg 2012 Aug;36(8):1958-62. SCI.

78.     Yeh YS, Chen MJ, Tsai HL, Huang MY, Chen CW, Huang YH, Sheen MC, Wang JY*. Transanal inside out rectal resection for ultra-low rectal cancer. J Invest Surg 2012 Dec;25(6):375-80. DOH101-TD-C-111-002. SCI.

79.     Lin HL, Chen CW, Lu CY, Sun LS, Shih YL, Chuang JF, Huang YH, Sheen MC, Wang JY*. Elevated Preoperative Blood Urea Nitrogen-to-Creatinine Ratio Increased Mortality in Gastrointestinal Cancer Patients Developing Enteric Fistula. Kaohsiung J Med Sci 2012 Aug;28(8):418-22. DOH100-TD-C-111-002. SCI.

80.     Kuo TY, His E, Yang IP, Tsai PC, Wang JY*, Suh-Hang Hank Juo*. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS ONE 2012;7(2):e31587. NSC99-2320-B-037-014-MY3, NSC94-2314-B037-104, DOH100-TD-C-111-002. SCI. (Equally corresponding authors).

81.     Yang PF, Chen CY, Yu FJ, Yang SF, Chen YT, Kao LC, Wang JY*. A rare complication of Meckel’s diverticulum: a fistula between Meckel’s diverticulum and the appendix. Asian J Surg 2012 Oct;35:163-65. DOH101-TD-C-111-002. SCI.

82.     Huang CW, Sun LC, Shih YL, Tsai HL, Chen CW, Yeh YS, Ma CJ, Huang CJ, Wang JY*. The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer. World J Surg Oncol 2012 May 3;10(1):76. DOH101-TD-C-111-002. SCI.

83.     Wu TY, Yang IH, Tsai YT, Wang JY, Shiurba R, Hsieh TJ, Chang FR*, Chang WC*. Isodesacetyluvaricin, an annonaceous acetogenin, specifically inhibits gene expression of cyclooxygenase-2. J Nat Prod. 2012 Apr 27;75(4):572-6. SCI.

84.     Tsai HL, Chen MJ, Yeh YS, Chen CW, Sun LC, Lu CY, Wang JY*. The comparison of minilaparotomy with conventional laparotomy as the surgical approach in stage I-III colorectal cancer patients: appealing outcomes. Hepato-Gastroenterology 2012 Feb;10;59(119). DOH101-TD-C-111-002. SCI

.85.     Chen CF, Huang MY, Huang CJ, Wu CH, Yeh YS, Tsai HL, Ma CJ, Lu CY, Chang SJ, Chen MJ, Wang JY*. An observational study of the efficacy and safety of capecitabine versus bolus infusional 5-Fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer Int J Colorectal Dis 2012 Jun;27(6):727-36. DOH101-TD-C-111-002. SCI.

86.     Huang MY, Huang ML, Wang JY*, Lin SR*. Investigation of vascular invasion and genetic polymorphisms of DPD IVS14+1 G>A, UGT1A1 3156 G>A, and UGT1A1 28 tandem repeats in colorectal cancer patients in Taiwan. Genomic Med Bio Mark Health Sci 2012;4:28-29. DOH101-TD-C-111-002.

87.     Tung TC, Lin SR, Wang JY, Chung FY. The use of multiple molecular markers as predictors of the clinical prognosis of patients with colorectal cancer. Genomic Med Bio Mark Health Sci 2012;4:30-33.

88.     Hung HC, Yen LC, Lin SR, Wang JY. Multiple mRNA markers for the detection of circulating tumor cells in breast cancer patients. Genomic Med Bio Mark Health Sci 2012;4:34-37.

89.     Chen CF, Wong WY, Chuang CH, Yeh YS, Tsai KB, Wang JY*. Ruptured ovarian yolk sac tumor combined with hemoperitoneum in a young girl with abdominal blunt injury Genomic Med Biomark Health Sci 2012;4:76-78. DOH101-TD-C-111-002.

90.     Ma CJ, Sun LC, Chen FM, Lu CY, Shih YL, Tsai HL, Chuang JF, Wang JY*. A Double-Blind Randomized Study Comparing the Efficacy and Safety of a Composite vs a Conventional Intravenous Fat Emulsion in Postsurgical Gastrointestinal Tumor Patients. Nutr Clin Pract 2012 Jun;27(3):410-5. DOH101-TD-C-111-002. SCI.

91.     Huang MY, Wang HM, Tok TS, Chang HJ, Chang MS, Cheng TL, Wang JY*, Lin SR*. EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol 2012 Apr;31(4):625-35. DOH100-TD-C-111-002. SCI.

92.     Wang JY, Chen BK, Wang YU, Tsai YT, Chen WC, Chang WC, Hou MF, Wu YC, Chang WC*. Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cellular Signalling 2012 Jan;24(1):162-9. NSC 100-2320-B-037-002, 353 NSC 99-2911-I-037-003, KMUH98-8I04, DOH100-TD-C-111-002. SCI.

93.     Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY*. Prospective analysis of KRAS wild-type status in patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 regimen as the second/third-line setting. Genet Mol Res 2011 Oct 3;10(4):3002-12. NSC99-2320-B-037-014-MY3. DOH100-TD-C-111-002. SCI.

94.     Lu CY, Uen YH, Tsai HL, Chuang SC, Hou MF, Wu DC, Juo SH, Lin SR, Wang JY*. Molecular detection of persistent postoperative circulating tumor cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer 2011 Feb;104:1178–1184. NSC99-2320-B-037-014-MY3, 98CM-KMU-13 & DOH100-TD-C-111-002. SCI.

95.     Huang MY, Wang HM, Chang HJ, Hsiao CP, Wang JY*, Lin SR*. Overexpression of S100B, TM4SF4 and OLFM4 Genes are Correlated with Liver Metastasis in Taiwanese Colorectal Cancer Patients. DNA Cell Biol 2012 Jan;31(1):43-9. NSC 99-2320-B-037-014-MY3, DOH100-TD-C-111-002. SCI.

96.     Yeh YS, Wang HM, Lin SR, Wang JY*. Prognostic and Molecular Factors in Stage II Colorectal Cancer. Genomic Med Bio Mark Health Sci 2011;3:2-8. (Review article).

97.     Huang MY, Wang JY, Chang HJ, Kuo CW, Tok TS, Lin SR. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer. Oncol Rep 2011 May;25(5):1297-309. SCI.

98.     Huang WC, Chai CY, Chen WC, Hou MF, Wang YU, Chiu YC, Lu SR, Chang WC, Juo SH, Wang JY, Chang WC*. Histamine regulates cyclooxygenase 2 gene activation through Orai1-mediated NB activation in lung cancer cells. Cell Calcium. 2011 Jul;50(1):27-35. DOH100-TD-C-111-002. NSC 98-2320-B-037-028-MY2. SCI.

99.     Hwang CC, Chai HT, Chen HW, Tsai HL, Lu CY, Yu FJ, Huang MY, Wang JY*. S100B Protein Expressions as an Independent Predictor of Early Relapse in UICC Stages II and III Colon Cancer Patients after Curative Resection. Ann Surg Oncol 2011 Jan;18:139-145. SCI. KMUH98-8I04 & DOH99-TD-C-111-002.

100.  Huang CC, Ma CJ, Huang WT, Chan TF, Wang JY*. Primary malignant mixed Müllerian tumor arising from the mesorectum with a synchronous ovarian cancer: a case report and review of the literature. J Med Case Reports. 2011 Jan 18;5(1):15. PMID: 21244653. DOH100-TD-C-111-002.

101.  Chuang SC, Su YC, Lu CY, Hsu HT, Sun LC, Shih YL, Ker CG, Hsieh JS, Lee KT, Wang JY*. Risk factors for the development of metachronous liver metastasis in colorectal cancer patients after curative resection. World J Surg 2011 Feb;35(2):424-9. SCI. KMUH98-8I04 & DOH99-TD-C-111-002.

102.  Huang MY, Huang ML, Chen MJ, Lu CY, Chen CY, Tsai PC, Chuang SC, Hou MF, Lin SR, Wang JY*. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenetics and Genomics. Pharmacogenet Genomics. 2011 Jan;21(1):18-25. SCI. KMUH98-8I04, ZAFGH 100-05 & DOH99-TD-C-111-002.

103.  Lu CY, Shih YL, Sun LC, Chuang JF, Ma CJ, Chen FM, Wu DC, Hsieh JS, Wang JY*. The Inflammatory Modulation Effect of Glutamine-enriched Total Parenteral Nutrition in Postoperative Gastrointestinal Cancer Patients. Am Surg 2011 Jan;77(1):59-64. (corresponding author). SCI.

研討會論文發表(近五年)

Go to top